the abcellera biologics ( acc ) company is a new technology technology technology that is based on partnerships that are centered around partnerships. we have developed a unique business model that can accelerate drug discovery across the industry. we have developed a unique business strategy that can accelerate drug discovery across the industry, and we believe that this is best done in a partnership model. we have successfully developed two key acquisitions, orthomab and trianni, and we have successfully acquired trianni and increased our capacity and equipment to strengthen our team and technology platform. we ended the year with nearly $600 million in cash and over 200 million in accounts receivable. this provides a strong cash position which we will execute our plan for future growth.